Alterity Therapeutics Limited (ATHE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
460 Bourke Street
Melbourne, VIC 3000
Australia
Phone
61 3 9349 4906
Sector
Healthcare
Industry
Biotechnology
Employees
10
First IPO Date
September 29, 2003
| Name | Title | Pay | Year Born |
| David A. Stamler | CEO & Director | 783,530 | 1961 |
| Rudolph Emile Tanzi | Chief Scientific Advisor and Member of Research & Development Advisory Board | 0 | 1959 |
| Robert Cherny | Head of Research | 0 | N/A |
| Abby Macnish Niven | Chief Financial Officer & Company Secretary | 0 | 1983 |
| Steven D. Targum | Chief Medical Advisor | 0 | N/A |
Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.